OTC · Biotechnology

Finch Therapeutics Group, Inc. (FNCHQ) Stock

$10.20 +0.49% OTC: FNCHQ Healthcare

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs.

Valuation

MetricValue
Price$10.20
Market Cap$16.38M
P/E Ratio-1.18
P/B Ratio1.80
P/S Ratio0.00
EPS (TTM)$-8.64
52-Week High$16.10
52-Week Low$2.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-86.83%
ROA-27.89%
ROCE-40.49%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity3.06
Current Ratio3.39

Annual Financials (USD)

Metric20202021202220232024
Revenue$8.0M$19.0M$1.0M$0$0
Operating Profit$-39.0M$-60.0M$-95.0M$-34.0M$-19.0M
Net Profit$-39.0M$-58.0M$-115.0M$-75.0M$-14.0M
EPS$-24.39$-36.72$-72.12$-46.59$-8.64
Op Margin-510.9%-323.7%-11047.6%-31777.6%—

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$165.0M$225.0M$163.0M$55.0M$50.0M
Total Liabilities$261.0M$23.0M$67.0M$32.0M$41.0M
Cash$100.0M$133.0M$71.0M$25.0M$10.0M
Borrowings$2.0M$6.0M$52.0M$30.0M$28.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-31.0M$-67.0M$-75.0M$-32.0M—
Investing Cash Flow$-5.0M$-32.0M$-4.0M$1.0M—
Financing Cash Flow$0$1.0M$0$-1.0M—
Net Cash Flow$58.0M$36.0M$-62.0M$-46.0M—
Free Cash Flow$-34.0M$-83.0M$-77.0M$-32.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-2.47
FCF Yield-192.35%
Quick Ratio3.39
Interest Coverage0.00
Return 1Y-16.67%
Return 3Y54.55%
Return 5Y-97.57%

Ownership

Insiders Held0.00%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
Guggenheim Active Allocation Fund12026-05-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BMEA $1.80 +7.14% -1.20 $130.14M 0.00%
CNTB $2.36 +7.27% -2.31 $148.59M 0.00%
EWTX $42.25 +1.15% -22.58 $4.55B 0.00%
HOWL $0.96 +1.75% -0.33 $46.53M 0.00%
IMA $5.02 -1.57% -1.49 $56.62M 0.00%

About Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.

Finch Therapeutics Group, Inc. is headquartered in US.

Finch Therapeutics Group, Inc. (FNCHQ) stock trades at $10.20 with a market capitalization of $16.38M. The stock is valued at a price-to-earnings (P/E) ratio of -1.18, price-to-book of 1.80, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.00 and $16.10, and currently trades 36.6% below its 52-week high.

On profitability, Finch Therapeutics Group, Inc. generates a return on equity (ROE) of -86.83%, return on capital employed of -40.49%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.finchtherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides